Hoen Lukas, Lartey Sarah, Zhou Fan, Pathirana Rishi D, Krammer Florian, Mohn Kristin G-I, Cox Rebecca J, Brokstad Karl A
Influenza Centre, Department of Clinical Science, University of Bergen, Haukelandsbakken, 5009 Bergen, Norway.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Vaccines (Basel). 2024 Aug 1;12(8):864. doi: 10.3390/vaccines12080864.
Live attenuated influenza vaccines (LAIV) typically induce a poor hemagglutination inhibition (HI) response, which is the standard correlate of protection for inactivated influenza vaccines. The significance of the HI response is complicated because the LAIV vaccine primarily induces the local mucosal immune system, while the HI assay measures the circulating serum antibody response. However, age and pre-existing immunity have been identified as important factors affecting LAIV immunogenicity. This study aimed to extend our understanding of LAIV-induced immunity, particularly, the impact age and pre-existing immunity have on eliciting functional and neutralising antibody responses in paediatric and adult populations vaccinated with LAIV. Thirty-one children and 26 adults were immunized with the trivalent LAIV during the 2013-2014 influenza season in Norway. Children under 9 years received a second dose of LAIV 28 days after the first dose. Blood samples were collected pre- and post-vaccination. HI, microneutralization (MN) and enzyme-linked lectin assay for neuraminidase (NA) antibodies were measured against the vaccine strains. IgG antibody avidity against hemagglutinin (HA) and NA proteins from the vaccine strains was also assessed. Significant correlations were observed between HI and MN responses to A/California/7/2009 (A/H1N1)pdm09-like strain and B/Massachusetts/2/2012-like strain, suggesting that MN is a potential immunological correlate for LAIV. However, the relationship between recipient age (or priming status) and serological response varied between vaccine strains. There was a notable increase in HI and MN responses in all cohorts except naive children against the H1N1 strain, where most recipients had responses below the protective antibody threshold. NAI responses were generally weak in naive children against all vaccine strains compared with adults or antigen-primed children. Post-vaccination antibody avidity increased only in primed children below nine years of age against the A/H1N1 strain. Overall, our findings indicate that LAIV elicits functional and neutralizing antibody responses in both naive and antigen experienced cohorts, however, the magnitude and kinetics of the response varies between vaccine strains.
减毒活流感疫苗(LAIV)通常诱导出较差的血凝抑制(HI)反应,而HI反应是灭活流感疫苗保护作用的标准相关指标。HI反应的意义较为复杂,因为LAIV疫苗主要诱导局部黏膜免疫系统,而HI检测测量的是循环血清抗体反应。然而,年龄和既往免疫已被确定为影响LAIV免疫原性的重要因素。本研究旨在扩展我们对LAIV诱导免疫的理解,特别是年龄和既往免疫对接种LAIV的儿童和成人人群中引发功能性和中和抗体反应的影响。2013 - 2014年流感季节期间,挪威的31名儿童和26名成人接种了三价LAIV。9岁以下儿童在第一剂接种28天后接种第二剂。在接种疫苗前后采集血样。针对疫苗株检测HI、微量中和(MN)以及神经氨酸酶(NA)抗体的酶联凝集试验。还评估了针对疫苗株血凝素(HA)和NA蛋白的IgG抗体亲和力。观察到针对A/加利福尼亚/7/2009(A/H1N1)pdm09样株和B/马萨诸塞/2/2012样株的HI和MN反应之间存在显著相关性,表明MN是LAIV的潜在免疫相关指标。然而,疫苗株之间,受种者年龄(或免疫状态)与血清学反应的关系有所不同。除了未接触过抗原的儿童外,所有队列针对H1N1株的HI和MN反应均有显著增加,其中大多数受种者的反应低于保护性抗体阈值。与成人或已接触过抗原的儿童相比,未接触过抗原的儿童针对所有疫苗株的NAI反应通常较弱。接种疫苗后,仅9岁以下已接触过抗原的儿童针对A/H1N1株的抗体亲和力有所增加。总体而言,我们的研究结果表明,LAIV在未接触过抗原和已接触过抗原的队列中均能引发功能性和中和抗体反应,然而,不同疫苗株的反应强度和动力学有所不同。